Soligenix, Inc.'s President and CEO Christopher Schaber will present at the 17th BIO CEO & Investor Conference at 1:30 p.m. EST on Feb. 10.
The presentation will be available via webcast live and for one hour after its conclusion on the company's investor page.
Schaber's presentation will cover recent products in development and their progress and data from the most recent trials for each respective vaccine and therapeutic treatment.
Soligenix's business focus has been on the development of vaccines for infectious agents and chemical threats. These include vaccines to prevent the effects of ricin and against anthrax. Also in development are therapeutic candidates for melioidosis, gastrointestinal disorders such as Crohn's Disease and a new treatment for cutaneous T-cell lymphoma that utilizes visible light.
The BIO CEO & Investors Conference brings together investors and publicly traded biotechnology companies. The conference allows a fair view of investment opportunities within the industry.
In 2014, more than 1,400 attendees representing 26 countries attended. Of those attendees, approximately 750 were investors.
This year's conference is Feb. 10-11 at the Waldorf Astoria hotel in New York. Schaber's presentation will be held in the Conrad room.